Advanced Search: DT/Phase 1

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201407100

A PHASE 1B CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNE RESPONSE TO A MAMMAGLOBIN-A DNA VACCINE IN ER+, HER2- BREAST CANCER PATIENTS UNDERGOING NEOADJUVANT ENDOCRINE THERAPY OR CHEMOTHERAPY

201508140

A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV associated Solid Tumors with Expansion Cohorts in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma

201703028

Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

201711014

A Phase 1, Multicenter, Dose-escalation and Expansion Study of ARX788 as Monotherapy in Advanced Solid Tumors with HER2-expression or Mutation

201904008

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

201905001

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors

201909144

A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors

201912015

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy

201904006

A multicentre, open-label, non-randomised first in human study of NG-641, an oncolytic transgene expressing adenoviral vector, in patients with epithelial tumours

201911172

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 in Subjects with Advanced Solid Malignancies including Lymphoma